Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Report on Business

Streetwise

News and analysis on Bay Street and the world of finance
available exclusively to subscribers of Globe Unlimited

Entry archive:

DiagnoCure hires U.S. dealer for expansion Add to ...

Quebec's own DiagnoCure Inc. , which markets a colorectal cancer screening test, announced Tuesday it hired San Francisco-based JMP Securities to gain some traction in its U.S. subsidiary, DiagnoCure Oncology Laboratories.

The firm is staying mum about what exactly it wants JMP to do, but the U.S. dealer specializes in health care.

DiagnoCure's stock has moved sideways since the start of 2009. After trying to gain ground in Canada, the firm now sees much more potential south of the border where insurance companies are more willing to experiment with new procedures. Tuesday's announcement came after Valerie Palmieri was recently hired in April to head the U.S. operations.

In 2008 DiagnoCure launched a new colorectal screening test, known as Previstage, that screens colon tumours and the lymph nodes. The company said currently around 25 per cent of people who have a tumour in this region are told that the cancer hasn't spread, even though it actually has, because current screening measures aren't advanced enough. To prevent this, DiagnoCure's test looks much deeper into the tissue.

Follow on Twitter: @timkiladze

 
Security Price Change
CUR-T DiagnoCure Inc. 0.15 0.0000
0.00 %
Add to watchlist
Live Discussion of CUR on StockTwits
More Discussion on CUR-T

In the know

Most popular video »

Highlights

More from The Globe and Mail

Most Popular Stories